Stephen F. Austin State University SFA ScholarWorks

Faculty Publications

Forestry

2013

[6]-Gingerol: A Novel AT1 Antagonist for the Treatment of Cardiovascular Disease (Abstract)

Qing Liu

Key Laboratory of TCM-information Engineer of State Administration of TCM, School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100102, China

Jinjin Liu Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

Haili Guo Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

Shengnan Sun Key Laboratory of TCM-information Engineer of State Administration of TCM, School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100102, China

Shifeng Wang Key Laboratory of TCM-information Engineer of State Administration of TCM, School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 100102, China

Follow this and additional works at: https://scholarworks.sfasu.edu/forestry

Part of the Pharmacology, Toxicology and Environmental Health Commons

Tell us how this article helped you.

Repository Citation

Liu, Qing; Liu, Jinjin; Guo, Haili; Sun, Shengnan; Wang, Shifeng; Zhang, Yanling; Li, Shiyou; and Qiao, Yanjiang, "[6]-Gingerol: A Novel AT1 Antagonist for the Treatment of Cardiovascular Disease (Abstract)" (2013). *Faculty Publications*. 434.

https://scholarworks.sfasu.edu/forestry/434

This Article is brought to you for free and open access by the Forestry at SFA ScholarWorks. It has been accepted for inclusion in Faculty Publications by an authorized administrator of SFA ScholarWorks. For more information, please contact cdsscholarworks@sfasu.edu.

Authors

Qing Liu, Jinjin Liu, Haili Guo, Shengnan Sun, Shifeng Wang, Yanling Zhang, Shiyou Li, and Yanjiang Qiao

Planta Med 2013; 79(05): 322-326 DOI: 10.1055/s-0032-1328262 Georg Thieme Verlag KG Stuttgart · New York

[6]-Gingerol: A Novel AT1 Antagonist for the Treatment of Cardiovascular Disease

Qing Liu¹, Jinjin Liu², Haili Guo², Shengnan Sun², Shifeng Wang¹, Yanling Zhang¹, Shiyou Li², Yanjiang Qiao¹

- ¹ School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, China
- ² Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

Abstract

Considering the prevalence of cardiovascular disease in public health and the limited validated therapeutic options, this study aimed to find novel compounds targeting the angiotensin II type 1 receptor, accepted as a therapeutic target in cardiovascular disease. A small library consisting of 89 compounds from 39 Chinese herbs was profiled using a cell-based calcium mobilization assay which was developed and characterized for high-throughput screening. [6]-Gingerol derived from Zingiber officinale Roscoe (ginger) was identified as a novel angiotensin II type 1 receptor antagonist, with an IC₅₀ value of 8.173 μ M. The hit was further tested by a specificity assay indicating that it had no antagonistic effects on other evaluated GPCRs, such as endothelin receptors. The major ingredient of ginger, [6]-gingerol, could inhibit angiotensin II type 1 receptor activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.

Key words

 $[6]\mbox{-gingerol}$ - AT_1 antagonist - calcium assay - high-throughput screening - cardiovascular disease - Chinese herb